RxSight, Inc.
Close on Oct 19, 2026
- Market cap
- $194.59M
- P/E (TTM)
- –
- Dividend yield
- –
About RxSight
Ophthalmic Goods, SIC 3851
RxSight, Inc. is a commercial-stage medical technology company that provides customized vision solutions to patients following cataract surgery. The company develops, manufactures, and markets the proprietary RxSight Light Adjustable Lens system, an adjustable intraocular lens technology. This system includes the Light Adjustable Lens, the Light Delivery Device, and associated accessories. The technology allows ophthalmic surgeons to modify lens power and astigmatic correction non-invasively through ultraviolet light treatments after surgical implantation, rather than relying exclusively on preoperative estimates. Its primary customers are ophthalmologists and cataract surgeons, as well as ophthalmic practices and ambulatory surgery centers.
The company focuses its commercial operations primarily in the United States through a direct sales team, clinical specialists, and field service personnel. Its sales target high-volume cataract surgeons who perform premium intraocular lens procedures. As of December 31, 2025, the company had an installed base of 1,134 Light Delivery Devices across ophthalmology practices. The provided text does not mention the location of the company's headquarters.
Summary of the business section of RxSight's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RxSight, Inc.
- Headquarters
- Aliso Viejo, CA
- Address
- 100 Columbia Street, Suite 120 92656
- Phone
- (949) 521-7822
- Employees
- 461, Dec 31, 2025
- Industry
- Ophthalmic Goods
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Irvine, California
Stock & identifiers
- Ticker
- RXST
- Exchange
- Nasdaq
- IPO date
- Jul 30, 2021
- Shares outstanding
- 42M, Jul 31, 2026
- Public float
- $503.80M, Jun 30, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1111485
- CUSIP
- 78349D107
- ISIN
- US78349D1072
- EIN
- 94-3268801
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Aziz Mottiwala | President and CEO, Director | – |
| Eric Weinberg | See remarks | 536,419 |
| Mark Wilterding | Chief Financial Officer | 25,049 |
| Ilya Goldshleger | Chief Operating Officer | 82,881 |
| Ronald M. Kurtz MD | Chief Medical Officer | 836,385 |
| Scott Gaines | Chief Customer Officer | 17,428 |
| Shelley B. Thunen | See remarks | 38,354 |
| Bakker Juliet Tammenoms | Director | 86,731 |
| Robert J. Palmisano | Director | 78,076 |
| Julie Andrews | Director | 78,076 |
| Jesse Anderson Corley | Director | 108,145 |
| Robert Keith Warner | Director | 78,076 |
| Shweta Maniar | Director | 55,172 |
| Tamara Fountain | Director | 72,582 |
| Raymond W. Cohen | Director | 66,532 |
| William J. Link Phd | Director | 96,140 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $4.65M | -$2.16M | $2.48M | $93 | $76 |
| FY2024 | $6.98M | $5.12M | $5.80M | $306 | $76 |
| FY2023 | $3.08M | $11.80M | $1.81M | $358 | $72 |
| FY2022 | $1.03M | $1.25M | $649.36K | $113 | $77 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 461 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 30, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 28, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Mar 20, 2014 | Name change | Name changed from CALHOUN VISION INC to RxSight, Inc. |